A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ixchiq
Synonyms :
chikungunya vaccine
Class :
Vaccines, Live, Viral
Dosage Forms & Strengths
Intramuscular injection
(Every single-dose vial includes a live lyophilized antigen component)
Recommended for people over the age of 18 who are more likely to be exposed to the chikungunya virus (CHIKV) in order to prevent disease caused by these virus
Administer dose of 0.5 ml intramuscularly as single dose
Safety & efficacy not established
Refer adult dosing
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may reduce the therapeutic efficacy of the drug
acetaminophen: they may decrease the therapeutic effect of vaccines
cladribine: they may decrease the therapeutic effect of vaccines
corticosteroids: they may decrease the therapeutic effect of vaccines
corticosteroids: they may decrease the therapeutic effect of vaccines
corticosteroids: they may decrease the therapeutic effect of vaccines
corticosteroids: they may decrease the therapeutic effect of vaccines
corticosteroids: they may decrease the therapeutic effect of vaccines
methotrexate: they may decrease the therapeutic effect of vaccines
teplizumab: they may decrease the therapeutic effect of vaccines
fingolimod: they may decrease the therapeutic effect of vaccines
propacetamol: they may decrease the therapeutic effect of vaccines
siponimod: they may decrease the therapeutic effect of vaccines
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
dupilumab: they may increase the toxic effect of vaccines
famciclovir: they may increase the toxic effect of vaccines
ozanimod: they may increase the toxic effect of vaccines
tezepelumab: they may increase the toxic effect of vaccines
may diminish the immunosuppressive effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
dimethyl fumarate: they may increase the toxic effect of vaccines
leniolisib: they may increase the toxic effect of vaccines
Actions and Spectrum:Â
A chikungunya vaccine works by inducing the immune system to mount a targeted defence against the chikungunya virus.
The vaccine stimulates the immune system to produce antibodies that can fend off the virus if the patient is subsequently exposed to it by injecting a harmless fragment of the chikungunya virus or a weakened form of the virus into the body.Â
The range of viral strains or subtypes that a chikungunya vaccine can defend against is referred to as the vaccine’s spectrum.Â
Frequency defined
>10%
Headache (31.6%)
Myalgia/muscle pain (23.9%)
Fatigue (28.5%)
Fever (13.5%)
Injection site tenderness (10.6%)
Nausea (11.2%)
1-10%
Injection site pain (6.2%)
Rash (2.3%)
Vomiting (1.9%)
Fever, severe (1.4%)
Injection site induration, ≥2.5 cm (1.4%)
None
Contraindication / Caution:
After receiving Ixchiq or any other vaccine, an acute anaphylactic reaction requires prompt medical attention due to immediate allergic reactions.
Ixchiq may result in severe or protracted side effects that mimic chikungunya. Approximately 1.6% of the 3,082 recipients of Ixchiq experienced severe adverse reactions similar to chikungunya, which affected their daily activities and necessitated medical intervention; in contrast, the placebo group did not experience any such incidents.
After taking Ixchiq, 14 people experienced side effects similar to chikungunya that persisted for at least 30 days.
Pregnant women should weigh the risks and benefits of using Ixchiq during their pregnancy, taking into account their gestational age and the likelihood that they will contract chikungunya.
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: Â
Virus-like particles (VLPs) that resemble the chikungunya virus but do not spread illness make up the vaccine. The immune system produces an immunological reaction once the vaccine is introduced into the body because it detects the VLPs as being alien. The development of antibodies that can precisely identify and neutralize the chikungunya virus if a person is exposed to it in the future is a component of this response.Â
Pharmacodynamics:Â
The biochemical and physiological reactions a chikungunya vaccine has on the body, particularly the immune system, to generate protection against the virus are referred to as its pharmacodynamics.Â
The B-cell activation that occurs as a result of this immune response results in the production of antibodies that are tailored to the chikungunya virus. These antibodies can then neutralise the virus and stop it from spreading and infecting others.Â
Pharmacokinetics:Â
Absorption Â
An intramuscular injection is used to provide the chikungunya vaccine, often in the arm. This enables the vaccine to be administered directly into the muscle tissue, which may aid in bloodstream absorption.Â
Distribution Â
The vaccine particles get into the bloodstream and then circulate throughout the body, reaching different organs and tissues.Â
MetabolismÂ
Virus-like particles (VLPs), which resemble the chikungunya virus but do not spread disease, make up the chikungunya vaccine. These VLPs trigger an immunological response rather than being digested by the body.Â
Elimination and Excretion Â
The virus like particles in the chikungunya vaccine are removed by the immune system naturally rather than being digested or broken down by the body.Â
Administration: Â
Combine the lyophilized antigen component with a sterile water diluent component and reconstitute it separately.
After lyophilized antigen is reconstituted, it should take the form of a clear, colorless, to slightly yellowish liquid solution. Lyophilized antigen is a white to light yellowish powder.
Look for discoloration and particulate matter with your eyes; if you find either, don’t give anything.
Lyophilized powder should be reconstituted:
Cleanse the lyophilized antigen component’s vial stopper.
Carefully fill the vial with the full sterile water diluent from the prefilled syringe.
Keep the needle in the vial.
Swirl the vial gently to dissolve the lyophilized powder; DO NOT shake or invert the container.
Wait for the vaccine to fully reconstitute after swirling for at least one minute.
Prepare the dosage:
Once the vial has been reconstituted, tilt it slightly and remove the entire contents into the needle.
Avoid inverting the vial.
Patient information leafletÂ
Generic Name: chikungunya vaccine
Why do we use chikungunya vaccine?Â
The use of the chikungunya vaccine is to produce acquired immunity to the chikungunya virus. A live, weakened strain of the chikungunya virus is included in the vaccine, which is injected into the muscle as a single dose. The vaccine recipient may develop symptoms that are comparable to those of chikungunya disease. Headache, fatigue, joint and muscle pain, fever, nausea, and soreness at injection site were the most frequently reported adverse effects among immunization recipients. For people 18 years of age and older who are at high risk of contracting the chikungunya virus, the vaccine is recommended as a means of preventing illness caused by the virus.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
